Head to Head Review: Halberd (OTCMKTS:HALB) & LianBio (NASDAQ:LIAN)

Halberd (OTCMKTS:HALB) and LianBio (NASDAQ:LIAN) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Earnings & Valuation

This table compares Halberd and LianBio”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halberd	N/A	N/A	N/A	($0.01)	-0.53
LianBio	N/A	N/A	-$110.29 million	($0.81)	-0.37

Halberd is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Halberd and LianBio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Halberd	N/A	N/A	N/A
LianBio	N/A	-33.17%	-30.19%

Analyst Ratings

This is a summary of recent recommendations for Halberd and LianBio, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halberd	0	0	0	0	N/A
LianBio	1	1	1	0	2.00

LianBio has a consensus target price of $5.33, suggesting a potential upside of 1,679.56%. Given LianBio’s higher probable upside, analysts clearly believe LianBio is more favorable than Halberd.

Institutional and Insider Ownership

74.8% of LianBio shares are owned by institutional investors. 75.6% of Halberd shares are owned by insiders. Comparatively, 7.6% of LianBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

About Halberd

Halberd Corporation, a biotech company, develops treatments for neurodegenerative diseases. It offers treatments for post traumatic stress disorder/chronic traumatic encephalopathy, Alzheimer's and Parkinson's disease, cancer, blood-borne, and cerebrospinal fluid related diseases. The company was incorporated in 2009 and is based in Jackson Center, Pennsylvania.

About LianBio

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.